[1] |
Invernizzi M, Lopez G, Michelotti A, et al. Integrating biological advances into the clinical management of breast cancer related lymphedema[J]. Front Oncol, 2020, 10:422.
|
[2] |
Thompson M, Korourian S, Henry-Tillman R, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation[J]. Ann Surg Oncol, 2007,14(6):1890-1895.
|
[3] |
徐宇,朱蕙燕,陈勇,等. 前哨淋巴结活检在中国皮肤和肢端恶性黑色素瘤患者诊治中的临床意义[J]. 中国癌症杂志,2018,28(11): 819-826.
|
[4] |
刘巍峰,杨发军,牛晓辉. 黑色素瘤前哨淋巴结活检和区域清扫的研究进展[J]. 中华肿瘤杂志,2019,41(7): 481-485.
|
[5] |
Ikeda K, Ogawa Y, Komatsu H, et al. Evaluation of the metastatic status of lymph nodes identified using axillary reverse mapping in breast cancer patients[J]. World J Surg Oncol, 2012, 10:233.
|
[6] |
Tausch C, Baege A, Dietrich D, et al. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients[J]. Eur J Surg Oncol, 2013, 39(8): 880-886.
|
[7] |
Yuan Q, Wu G, Xiao SY, et al. Identification and preservation of arm lymphatic system in axillary dissection for breast cancer to reduce arm lymphedema events: a randomized clinical trial[J]. Ann Surg Oncol, 2019, 26(11): 3446-3454.
|
[8] |
朱涛,徐洁,田甜,等. 逆行腋窝淋巴示踪术降低腋窝清扫术后乳腺癌相关上肢淋巴水肿风险:一项随机对照试验的系统评价和Meta分析[J]. 中国实用医刊,2019, 46(5): 76-79.
|
[9] |
Goffman TE, Laronga C, Wilson L, et al. Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery[J]. Breast J,2004,10(5):405-411.
|
[10] |
Foster D, Choy N, Porter C, et al. Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes[J]. J Surg Oncol,2018,117(3):336-340.
|
[11] |
Boneti C, Korourian S, Diaz Z, et al. Scientific impact award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy[J]. Am J Surg, 2009,198(4):482-487.
|
[12] |
Ahmed M, Rubio IT, et al. Systematic review of axillary reverse mapping in breast cancer[J]. Br J Surg, 2016,103(3):170-178.
|
[13] |
Pavlista D, Eliska O. Analysis of direct oil contrast lymphography of upper limb lymphatics traversing the axilla--a lesson from the past--contribution to the concept of axillary reverse mapping[J]. Eur J Surg Oncol, 2012, 38(5): 390-394.
|
[14] |
Ngui NK, French J, Kilby CJ, et al. Axillary reverse mapping in patients with breast cancer: is it oncologically safe[J]. J Surg Oncol, 2016, 113(7): 726-731.
|
[15] |
Suami H, Taylor GI, Pan WR. The lymphatic territories of the upper limb: anatomical study and clinical implications[J]. Plast Reconstr Surg, 2007, 119(6): 1813-1822.
|
[16] |
李琳,吴炅. 腋窝逆向淋巴示踪[J]. 外科理论与实践,2013,18(04): 400-404.
|
[17] |
钱军,张明亮,陈士文,等. 上臂淋巴回流与腋窝淋巴结的应用解剖关系及意义[J]. 蚌埠医学院学报,2019, 44(03): 281-283.
|
[18] |
刘媛,陆云飞. 腋窝逆向淋巴示踪的临床实践及争议[J/CD]. 中华乳腺病杂志(电子版), 2017, 11(6): 365-368.
|
[19] |
Nos C, Lesieur B, Clough KB, et al. Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection[J]. Ann Surg Oncol, 2007, 14(9): 2490-2496.
|
[20] |
刘佳勇,方志伟. 前哨淋巴结活检在皮肤恶性黑色素瘤中的应用现状及进展[J]. 中国肿瘤临床,2014, 41(12): 810-813.
|
[21] |
刘坚,李佳璐,周俊,等. 荧光法腋窝反向制图技术在乳腺癌手术中的可行性[J/CD]. 中华乳腺病杂志(电子版),2016,10(6): 333-339.
|
[22] |
Yang B, Zheng S, Huang X, et al. A single-center, self-controlled, phase I clinical trial of mitoxantrone hydrochloride injection for lymph tracing for sentinel lymph node identification of breast cancer[J]. Gland Surg, 2021, 10(3): 992-1001.
|
[23] |
贺青卿,朱见,庄大勇,等. 腋窝逆向淋巴示踪预防乳腺癌术后上肢水肿[J]. 国际外科学杂志,2013, 40(3): 209-211.
|
[24] |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12): 1303-1310.
|
[25] |
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol, 2019, 30(10): 1541-1557.
|
[26] |
Beek MA, Gobardhan PD, Klompenhouwer EG, et al. Axillary reverse mapping (ARM) in clinically node positive breast cancer patients[J]. Eur J Surg Oncol, 2015, 41(1): 59-63.
|
[27] |
Sun X, Wang XE, Zhang ZP, et al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial[J]. Breast Cancer Res Treat, 2020, 180(2): 423-428.
|
[28] |
Khandelwal R, Poovamma CU, Shilpy C, et al. Axillary reverse mapping: is it feasible in locally advanced breast cancer patients[J]. Breast Dis, 2014, 34(4): 151-155.
|
[29] |
Nos C, Kaufmann G, Clough KB, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection[J]. Ann Surg Oncol, 2008, 15(9): 2550-2555.
|
[30] |
邵志敏,江泽飞,李俊杰,等. 中国乳腺癌新辅助治疗专家共识(2019年版)[J].中国癌症杂志,2019,29(5): 390-400.
|
[31] |
Rupp J, Hadamitzky C, Henkenberens C, et al. Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast cancer - a long-term observation[J]. Radiat Oncol, 2019, 14(1): 39.
|
[32] |
Wang W, Ward R, Jia D, et al. Location of arm draining lymph node in relation to breast cancer radiotherapy field and target volume[J]. Radiother Oncol, 2019, 133:193-197.
|
[33] |
Gennaro M, Listorti C, Mariani L, et al. Oncological safety of selective axillary dissection after axillary reverse mapping in node-positive breast cancer[J]. Eur J Surg Oncol, 2021, 47(7):1606-1610
|